SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-006452
Filing Date
2022-02-10
Accepted
2022-02-10 16:35:35
Documents
15
Period of Report
2022-02-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea155330-8k_citiuspharma.htm   iXBRL 8-K 32611
2 PRESS RELEASE, DATED FEBRUARY 10, 2022 ea155330ex99-1_citiuspharma.htm EX-99.1 85257
3 GRAPHIC ex99-1_001.jpg GRAPHIC 4467
  Complete submission text file 0001213900-22-006452.txt   353874

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20220210.xsd EX-101.SCH 3737
5 XBRL DEFINITION FILE ctxr-20220210_def.xml EX-101.DEF 26822
6 XBRL LABEL FILE ctxr-20220210_lab.xml EX-101.LAB 36824
7 XBRL PRESENTATION FILE ctxr-20220210_pre.xml EX-101.PRE 25444
9 EXTRACTED XBRL INSTANCE DOCUMENT ea155330-8k_citiuspharma_htm.xml XML 5347
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

IRS No.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 22614562
SIC: 2834 Pharmaceutical Preparations